Recently, the U.S. Food and Drug Administration (FDA) officially approved Apple Watch’s ‘Atrial Fibrillation History’ feature as a medical device. In response, Apple stated that this approval marks a significant milestone in its digital health journey. The feature leverages the Apple Watch’s built-in electrocardiogram (ECG) sensor to proactively detect atrial fibrillation (AFib)—a common cardiac arrhythmia that can increase stroke risk. Unlike previous versions that only recorded data when users manually initiated a reading, the newly approved functionality continuously monitors heart rhythm in the background and alerts users if potential signs of AFib are detected. Apple emphasized that the technology is not intended for diagnosis but rather to help users identify irregularities early and seek timely medical attention. The company also noted that the underlying algorithm has been validated through large-scale clinical studies, demonstrating high accuracy and reliability. This FDA clearance not only enhances the Apple Watch’s value in personal health management but also offers consumers a more accessible and personalized health monitoring tool. Apple plans to roll out the feature to additional countries and regions and continues to explore the potential of wearable devices in chronic disease management and early intervention.
近日，美国食品药品监督管理局（FDA）正式批准苹果Apple Watch的‘房颤记录’功能作为医疗设备使用。对此，苹果公司迅速作出回应，表示这一批准标志着其在数字健康领域迈出的重要一步。该功能利用Apple Watch内置的心电图（ECG）传感器，可主动检测用户是否存在心房颤动（AFib）——一种常见且可能引发中风的心律失常。与以往仅在用户主动测量时记录不同，新获批的功能可在后台持续监测心率异常，并在发现潜在房颤迹象时发出提醒。苹果强调，该技术并非用于诊断，而是帮助用户及早发现异常并及时就医。公司还指出，相关算法已通过大规模临床研究验证，具备较高的准确性和可靠性。此次获批不仅提升了Apple Watch在健康管理方面的价值，也为消费者提供了更便捷、个性化的健康预警工具。未来，苹果计划将该功能推广至更多国家和地区，并继续探索可穿戴设备在慢性病管理和早期干预中的潜力。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/11309.html